BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Guangzhou Fermion Partners with Simcere to Advance Clinical-Stage SSTR4 Agonist for Pain Management

Guangzhou Fermion Technology Co., Ltd. and Simcere Pharmaceutical Group Limited have announced a partnership to develop a clinical-stage pain treatment ass...

January 20, 2025 | News

Eyebright Medical Secures NMPA Approval for Loong Crystal PR, a Cutting-Edge Solution for Myopia Correction

Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries coll...

January 08, 2025 | News

HKSH Cancer Centre Hosts Sixth Symposium on Cancer Management, Celebrates One Year of Proton Therapy Milestones

HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at ...

January 03, 2025 | News

Sanofi Acquires Greater China Rights for Aficamten from CORXEL, Expanding HCM Treatment Reach

Cytokinetics, Incorporated announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL...

December 20, 2024 | News

Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment

Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...

December 20, 2024 | News

Everest Medicines’ VELSIPITY® Prescribed in Mainland China, Pioneering New Ulcerative Colitis Treatment under Hong Kong-Macau Connect

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

December 18, 2024 | News

Everest Medicines Announces First Prescription of VELSIPITY® for Ulcerative Colitis in Macau, Marking a Key Milestone in Asia

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

December 13, 2024 | News

Hong Kong’s Viva Biotech Expands Global Footprint with Strategic Boston Branch Launch

Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug re...

December 12, 2024 | News

Alamar Biosciences Expands to APAC with ARGO™ HT System Installation at HKCeND

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in th...

December 09, 2024 | News

Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Approved for Pediatric Use in Hong Kong

Pfizer announced that the Hong Kong Department of Health (DoH) has approved its 20-valent Pneumococcal Conjugate Vaccine (PCV20) for active immunization in...

December 04, 2024 | News

Everest Medicines’ New Drug Application for VELSIPITY® (etrasimod) Accepted in Hong Kong for Ulcerative Colitis

Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...

December 03, 2024 | News

Merck and Abbisko Report Phase III Success for Pimicotinib in TGCT Treatment

Phase III MANEUVER study met primary endpoint, with an objective response rate at week 25 of 54.0% for pimicotinib versus 3.2% for placebo (p<0.0001) ...

November 27, 2024 | News

Akeso's Penpulimab and Anlotinib Combo Accepted by NMPA for First-Line Advanced Liver Cancer Treatment

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accep...

November 25, 2024 | News

Novotech and Biostar Announce Long-Term Partnership to Accelerate Oncology Clinical Development

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advan...

November 13, 2024 | News

Stay Connected